GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NLSP
NLS Pharmaceutics is a Swiss biotech company specializing in the treatment of sleep disorders. Its stock price is driven by news of clinical trials of its drugs. The chart reflects investor hopes for the development of new treatments for narcolepsy.
Share prices of companies in the market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs to treat rare sleep disorders and other central nervous system disorders. We've classified it in the Pharma: Neuroscience category. The chart below shows the dynamics in this niche segment.
Broad Market Index - GURU.Markets
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs to treat rare sleep disorders and other central nervous system disorders. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how NLS compares to it.
Change in the price of a company, segment, and market as a whole per day
NLSP - Daily change in the company's share price NLSP
For NLS Pharmaceutics AG, which develops sleep disorder medications, daily volatility reflects sensitivity to clinical trial data. This metric is an important element for assessing risks in this niche.
Daily change in the price of a set of shares in a market segment - Pharma neurology
NLS Pharmaceutics develops drugs to treat rare neurological diseases such as narcolepsy. The biopharmaceutical sector is known for its high volatility, driven by news. The chart below shows the average fluctuations in this niche and can help assess the risks and performance of NLSP stock.
Daily change in the price of a broad market stock, index - GURU.Markets
NLS Pharmaceutics is a Swiss biotech company specializing in the treatment of rare neurological diseases. Its shares are driven by news of clinical trials, adding an element of high scientific volatility to the overall market picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NLSP
NLS Pharmaceutics AG's year-to-date performance is a story of drug development for rare sleep disorders like narcolepsy. Its 12-month market cap is entirely dependent on clinical trial data. Success with its lead candidate could offer new hope for patients and represent a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma neurology
NLS Pharmaceutics is a late-stage biotech developing drugs for rare sleep disorders. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NLS Pharmaceutics, a company developing drugs to treat rare sleep and cognitive disorders, is a high-potential company. Comparing its annual market capitalization to the market shows how investors assess the chances of its drugs being approved. Share performance is heavily dependent on lab news rather than overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on CNS diseases. Its monthly performance is entirely dependent on the results of its clinical trials. News about its narcolepsy drugs is a key driver.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss clinical-stage biopharmaceutical company focused on developing treatments for rare sleep disorders and cognitive disorders. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess the progress of its leading candidates for the treatment of narcolepsy and ADHD in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on ADHD and narcolepsy. Its NASDAQ shares are driven by news of clinical trials. The chart shows the high volatility typical of biotech companies, whose value is a bet on the success of future drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NLSP
NLS Pharmaceutics, a Swiss biotech company developing drugs for sleep disorders and ADHD, exhibits high volatility. Its weekly stock price is almost entirely dependent on clinical trial results and regulatory decisions in the US and Europe, creating significant risks for investors.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
NLS Pharmaceutics, a Swiss biopharmaceutical company, develops drugs for the treatment of rare diseases of the central nervous system. The stock prices of companies like these are heavily dependent on news about trial progress. The chart shows whether weekly fluctuations are driven by general industry trends or by NLS-specific events.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs for the central nervous system. Its shares are driven by news about clinical trials, not by macroeconomic data. The chart shows how their performance is uncorrelated with overall market trends.
Market capitalization of the company, segment and market as a whole
NLSP - Market capitalization of the company NLSP
NLS Pharmaceutics' market capitalization represents the financial value of its hopes for new treatments for sleep disorders such as narcolepsy. The chart shows how investors value its lead drug, which may offer an improved safety profile. Its performance is highly sensitive to clinical trial results and regulatory decisions.
NLSP - Share of the company's market capitalization NLSP within the market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating rare sleep disorders and ADHD. Its market share is small, but it targets niches with unmet needs. Its market cap is based on the valuation of its leading candidates, which could offer new treatment options.
Market capitalization of the market segment - Pharma neurology
Below is a chart reflecting the combined weighting of the entire neuroscience pharmaceutical sector. For NLS Pharmaceutics, which develops drugs for sleep disorders and ADHD, this line is a map of hope. Its rise demonstrates how willing investors are to fund research in one of the most complex areas of medicine, where the need for new drugs is enormous.
Market capitalization of all companies included in a broad market index - GURU.Markets
NLS Pharmaceutics is a Swiss company developing drugs for the treatment of rare sleep disorders and ADHD. Its market capitalization reflects its scientific approach to neurological problems. This share is attributed to the search for solutions to improve concentration and rest.
Book value capitalization of the company, segment and market as a whole
NLSP - Book value capitalization of the company NLSP
NLS Pharmaceutics develops drugs to treat rare sleep disorders and ADHD. Its book value represents its financial resources for R&D. It consists of the cash needed to advance its candidates through clinical trials. How has this capital changed? The chart below shows.
NLSP - Share of the company's book capitalization NLSP within the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss company developing medications for sleep disorders and ADHD. Its research requires a lab to develop and test new formulas for central nervous system medications. The chart shows the company's share of the physical R&D infrastructure in this segment.
Market segment balance sheet capitalization - Pharma neurology
NLS Pharmaceutics is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. NLS focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
NLS Pharmaceutics' book value is not derived from its plants, but from capital invested in clinical trials of drugs for rare sleep disorders such as narcolepsy. Its assets reflect the financial resources for research in this complex area of neuroscience. The chart illustrates the scale of this Swiss biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company developing treatments for rare neurological disorders. Its market value is derived from its research and development pipeline. Investors are betting on the success of its clinical trials, not its current assets.
Market to book capitalization ratio in a market segment - Pharma neurology
NLS Pharmaceutics is a Swiss company developing drugs for the treatment of central nervous system disorders such as narcolepsy. Its high valuation on this chart reflects investors' faith in its scientific developments and potential to capture a niche but significant market, despite the risks of clinical trials.
Market to book capitalization ratio for the market as a whole
NLS Pharmaceutics, a Swiss biopharmaceutical company, focuses on treating central nervous system disorders. Its value is determined not so much by its lab equipment as by the potential of its developments. This metric illustrates the premium investors place on intellectual capital and prospects in the healthcare sector.
Debts of the company, segment and market as a whole
NLSP - Company debts NLSP
NLS Pharmaceutics, a Swiss biopharmaceutical company focused on treating sleep disorders and ADHD, is in the clinical stage. Its operations are entirely funded by raised capital, which is necessary for conducting expensive trials. This chart shows the company's financial needs during the long road to potential drug approval.
Market segment debts - Pharma neurology
NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on developing drugs to treat rare sleep-wake disorders such as narcolepsy. This chart shows how the company finances its expensive clinical trials, raising capital to bring potential new treatments to market for patients with disabilities.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NLSP
NLS Pharmaceutics is a Swiss company developing drugs for the treatment of rare sleep disorders and ADHD. Clinical trials in neuroscience are a lengthy and expensive process. This chart illustrates the company's reliance on debt financing to advance its drug candidates through the clinical trials to eventual approval.
Market segment debt to market segment book capitalization - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs to treat rare neurological disorders such as narcolepsy. This chart shows how the company finances its expensive clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
NLS Pharmaceutics is a Swiss company developing drugs to treat rare neurological disorders such as narcolepsy. Biotech research requires significant and long-term capital investment. Does the company use debt financing? This chart, which reflects the overall debt burden in the economy, provides context for assessing its financial stability.
P/E of the company, segment and market as a whole
P/E - NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs to treat rare sleep-wake disorders such as narcolepsy. This chart shows how investors evaluate its drug candidates. The evaluation is highly dependent on clinical trial results and regulatory decisions.
P/E of the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss biopharmaceutical company developing treatments for rare sleep disorders and other central nervous system disorders, such as narcolepsy and ADHD. This chart illustrates the average valuation in the neuroscience pharmaceuticals sector, where investors evaluate the potential of drugs to improve patients' quality of life.
P/E of the market as a whole
NLS Pharmaceutics AG is a Swiss biopharmaceutical company specializing in developing treatments for rare and complex central nervous system disorders, such as narcolepsy. This chart reflects investors' overall risk appetite. It helps understand whether NLSP's valuation is based on the potential of its drugs or whether it moves in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs to treat rare sleep disorders and other central nervous system disorders, such as ADHD. This chart shows investor expectations regarding the clinical trial success and commercial potential of their niche, yet in-demand, drugs.
%20P%2FE%20NLSP&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NLSP&v=1772545247766 "Chart of the company's future (projected) P/E NLSP")
Future (projected) P/E of the market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating rare sleep disorders and ADHD. Success depends on regulatory approval. The chart shows average profitability expectations in the sector. It helps understand how high investor stakes are in NLS's clinical programs compared to other neurobiotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772545247884 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating rare sleep disorders and other central nervous system disorders. This chart of overall risk appetite in the healthcare sector shows how willing investors are to fund companies with a highly specialized focus and long drug development cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772545247992 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NLSP
NLS Pharmaceutics AG is a Swiss clinical-stage biopharmaceutical company focused on the treatment of rare neurological disorders such as narcolepsy. Its financial indicators reflect research expenditures. This chart shows investments in the development of drugs that have the potential to significantly improve patients' quality of life and generate future profits.
Profit of companies in the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss biopharmaceutical company focused on developing drugs for the treatment of rare sleep disorders and other central nervous system disorders. This chart shows the overall profitability of the neuroscience pharmaceutical sector, where successful drug development for niche but underserved markets can be highly profitable.
Overall market profit
NLS Pharmaceutics AG is a Swiss biopharmaceutical company specializing in the treatment of rare neurological disorders. The company's success depends solely on the results of clinical trials and the approval of its drugs. This process is isolated from the macroeconomic trends shown in this chart, as demand for these treatments is stable.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating rare sleep-wake disorders such as narcolepsy. Future profits depend on the success of clinical trials and the commercialization of its drugs. This chart shows analysts' speculative expectations regarding the commercial potential of its neuroscience developments.
%20profit%20of%20the%20company%20NLSP&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NLSP&v=1772545248314 "Graph of future (projected) profit of the company NLSP")
Future (predicted) profit of companies in the market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs to treat rare sleep and cognitive disorders, such as narcolepsy and ADHD. Its success depends on clinical trial results. This chart shows revenue projections for the neuroscience pharmaceutical segment, providing context for evaluating NLS's innovative approaches.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772545248455 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
NLS Pharmaceutics AG is a Swiss biopharmaceutical company developing drugs for the treatment of rare sleep disorders and ADHD. Its future depends on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772545248508 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating rare CNS diseases. Revenue at the clinical stage is minimal or nonexistent. This chart reflects investor expectations only. Its significance is a speculative assessment of the scientific potential and the chances of approval and future sales of its drugs.
P/S market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on developing treatments for rare central nervous system disorders, such as narcolepsy and idiopathic hypersomnia. Their goal is to offer patients more effective therapies. This chart reflects the average revenue estimate for the sector, which helps assess the potential of NLS's development pipeline.
P/S of the market as a whole
NLS Pharmaceutics is a Swiss biopharmaceutical company specializing in developing treatments for rare sleep disorders and other central nervous system disorders. This chart highlights that the valuation of such clinical-stage companies is based on the potential of their scientific developments, not current revenue, which distinguishes them from most companies on the market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NLSP
NLS Pharmaceutics AG is a Swiss biopharmaceutical company focused on developing treatments for rare sleep-wake disorders such as narcolepsy. Its revenue valuation is crucial, reflecting investor expectations for the success of clinical trials and the commercial potential of its drugs in a niche but important pharmaceutical market.
%20P%2FS%20NLSP&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NLSP&v=1772545248680 "The graph of the company's future (projected) P/S NLSP")
Future (projected) P/S of the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss biopharmaceutical company developing treatments for rare sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the potential of its drug candidates to address these needs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772545248706 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs for the treatment of rare sleep disorders, such as narcolepsy. The company's future depends on the success of clinical trials and market entry. This graph of investor expectations reflects their belief that drugs for the treatment of central nervous system disorders have high commercial potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772545248792 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NLSP
This chart shows revenue for NLS Pharmaceutics, a Swiss biopharmaceutical company developing drugs to treat rare sleep and cognitive disorders such as narcolepsy and ADHD. Being in the clinical stage, the company may not have commercial revenue. The chart reflects financial activity related to research and development.
Sales of companies in the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss biopharmaceutical company focused on the treatment of rare central nervous system disorders, such as narcolepsy. Being in the clinical stage, it does not yet have revenue. Its future revenue will depend on the success of its lead candidate, Quilience, in clinical trials and its subsequent commercialization.
Overall market sales
NLS Pharmaceutics AG is a Swiss biopharmaceutical company specializing in the treatment of rare diseases of the central nervous system. Its success depends entirely on the results of clinical trials. This overall market situation is irrelevant for a company solving complex medical problems, where value is determined by scientific breakthroughs, not economic cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NLSP
NLS Pharmaceutics AG is a Swiss biopharmaceutical company specializing in the development of treatments for rare sleep and cognitive disorders, such as narcolepsy and ADHD. Future revenues are dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its drug candidates if approved by regulators.
%20sales%20of%20the%20company%20NLSP&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NLSP&v=1772545249017 "Schedule of future (projected) sales of the company NLSP")
Future (projected) sales of companies in the market segment - Pharma neurology
NLS Pharmaceutics AG develops drugs to treat rare sleep disorders and other central nervous system disorders. This chart shows the sales forecast for the neurological drug market. Is the need for new treatments growing, creating opportunities for innovative therapies? This reflects a general trend in the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772545249157 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs for the treatment of rare diseases of the central nervous system. Its success depends entirely on the results of clinical trials and regulatory approvals. The general economic trends reflected in this chart have no impact on patient demand for treatment of these conditions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772545249177 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NLSP
NLS Pharmaceutics AG is a Swiss biopharmaceutical company specializing in the treatment of rare sleep and cognitive disorders. This chart shows its financial trajectory during clinical development. Profitability is a future goal, dependent on successful trials and regulatory approval of its innovative central nervous system drugs.
Market segment marginality - Pharma neurology
NLS Pharmaceutics AG is a Swiss clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of rare sleep disorders and other central nervous system disorders. This chart reflects its current financial position, with profitability entirely dependent on future success in clinical trials and the commercialization of its products.
Market marginality as a whole
NLS Pharmaceutics AG, which develops drugs to treat rare sleep disorders and cognitive disorders, depends on successful clinical trials and capital raising. This total return chart reflects the investment climate. In a healthy economy, investors are more inclined to fund risky but promising neuroscience projects.
Employees in the company, segment and market as a whole
Number of employees in the company NLSP
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating sleep disorders and ADHD. Its small staff consists of highly qualified specialists. This graph shows how the team is expanding as its drugs advance through clinical trials in Europe and the US, a critical milestone for a startup.
Share of the company's employees NLSP within the market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company developing treatments for rare sleep and cognitive disorders. Its staff consists primarily of scientists and clinical research specialists. This chart reflects its share of the biotech labor market, a measure of the scale of its research and development activities and its focus on science.
Number of employees in the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss biopharmaceutical company developing drugs for the treatment of rare central nervous system diseases, such as narcolepsy. This chart shows its workforce in neurological pharmaceuticals. NLS's focus on orphan diseases allows it to operate in markets with high unmet need and less competition.
Number of employees in the market as a whole
NLS Pharmaceutics is a Swiss biopharmaceutical company focused on treating rare diseases of the central nervous system. Its staff consists of a small group of scientists, and its dynamics are determined by research progress. This graph shows macro trends, while NLS is an example of how employment in knowledge-intensive industries is not dependent on general cycles but is driven by discoveries.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NLSP (NLSP)
NLS Pharmaceutics is a Swiss biotech company developing treatments for sleep disorders and ADHD. Their entire value lies in their science. This chart shows the market's perceived value per scientist in their clinical development pipeline. This is a pure indicator of intellectual capital.
%20of%20the%20company%20NLSP%20(NLSP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NLSP-NLSP&v=1772545249678 "Chart of market capitalization per employee (in thousands of dollars) of the company NLSP (NLSP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
NLS Pharmaceutics (NLSP) is a biopharmaceutical company focused on treating rare diseases of the central nervous system. Its value per employee is a measure of its pipeline. If this value is above the industry average, investors may highly value the company's drugs for treating complex and rare diseases.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772545249696 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
NLS Pharmaceutics is a Swiss biopharmaceutical company developing drugs for the treatment of sleep disorders and ADHD. Its valuation is based on the potential of its clinical candidates. The chart shows a high valuation per employee, as the market is pricing in the future success of its developments, which could carve out a significant niche in neuroscience.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772545249807 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NLSP (NLSP)
NLS Pharmaceutics is a Swiss clinical-stage biotech company focused on treating sleep disorders and ADHD. This chart for NLS reflects research intensity, not profit. A negative number indicates how much capital is invested in each scientist and specialist to conduct expensive clinical trials.
%20Chart%20NLSP%20(NLSP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NLSP-NLSP&v=1772545249836 "Company Profit Per Employee (in thousands of dollars) Chart NLSP (NLSP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
NLS Pharmaceutics AG is a Swiss biopharmaceutical company working on the treatment of rare neurological diseases. For such niche players, team efficiency is critical, as resources are limited. This report reflects the financial return per specialist, allowing investors to evaluate R&D productivity and commercial potential compared to industry peers.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772545249927 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
NLS Pharmaceutics is a Swiss biotech company focused on central nervous system disorders such as narcolepsy. Their business is pure R&D, not manufacturing. Their staff consists of scientists, and revenue (if any) is generated from intellectual property. This chart, showing the market average per employee, highlights the uniqueness of the biotech model, which thrives on clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772545249935 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NLSP (NLSP)
NLS Pharmaceutics AG is a Swiss biopharmaceutical company focused on the treatment of sleep disorders and ADHD. At the clinical stage, this figure is negligible. Its true potential will be realized after commercialization, when revenue per employee could soar, demonstrating the value of their scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NLSP-NLSP&v=1772545249947 "Sales chart per company employee NLSP (NLSP)")
Sales per employee in the market segment - Pharma neurology
NLS Pharmaceutics is a Swiss clinical-stage biotech focused on treating rare sleep disorders (narcolepsy) and ADHD. The company has no commercial revenue. This chart, showing average productivity in the sector, serves as a benchmark for NLS's R&D staffing efficiency (burn rate) compared to other neuroscience biotechs.
Sales per employee for the market as a whole
NLS Pharmaceutics is a Swiss biotech company developing drugs for the treatment of rare sleep disorders (narcolepsy) and ADHD. At this stage, their business is purely R&D. This chart shows that the company is in the investment phase: its research team generates clinical trial data, not revenue.
Short shares by company, segment and market as a whole
Shares shorted by company NLSP (NLSP)
NLS Pharmaceutics (NLSP) is a Swiss biotech company specializing in the treatment of sleep disorders such as narcolepsy. This chart shows the volume of short positions. Bears may doubt the success of clinical trials for the company's key drugs or the ability of its products to compete with established treatments in this challenging market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NLSP-NLSP&v=1772545250221 "Short Shares Chart for the Company NLSP (NLSP)")
Shares shorted by market segment - Pharma neurology
NLS Pharmaceutics (NLSP) is a Swiss biotech company specializing in the development of drugs for the treatment of sleep disorders (narcolepsy) and ADHD. This chart aggregates short positions in the neuroscience biotech sector. It reflects the high level of risk and investor skepticism regarding the complexity of brain drug development.
Shares shorted by the overall market
NLS Pharmaceutics (NLSP) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NLSP (NLSP)
NLS Pharmaceutics (NLSP) is a Swiss company developing drugs to treat rare sleep disorders such as narcolepsy. This is a highly specialized neuroscience niche. This chart measures the rate of price change. It helps identify when the stock is "overheated" (above 70) due to pending trial data or "oversold" (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NLSP-NLSP&v=1772545250365 "RSI 14 indicator chart for the company's stock NLSP (NLSP)")
RSI 14 Market Segment - Pharma neurology
NLS Pharmaceutics is a Swiss biopharmaceutical company specializing in the treatment of rare sleep and cognitive disorders, such as narcolepsy and ADHD. This chart shows the overall momentum in the biotech "neuro" segment. It helps distinguish the reaction to NLSP news from general euphoria or panic across this complex industry.
RSI 14 for the overall market
NLS Pharmaceutics (NLSP) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NLSP (NLSP)
NLS Pharmaceutics is a Swiss biotech company developing drugs for the treatment of rare CNS disorders, such as narcolepsy (Mazindol) and ADHD. This chart shows the average analyst forecast. Their targets are based on the clinical trial results of its lead candidates and their market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NLSP-NLSP&v=1772545250606 "A chart showing analyst consensus forecasts for the expected stock price. NLSP (NLSP)")
The difference between the consensus estimate and the actual stock price NLSP (NLSP)
NLS Pharmaceutics is a Swiss biotech company focused on developing drugs for rare sleep disorders (narcolepsy) and ADHD. This chart shows the difference between the market valuation and the consensus estimate. It reflects how confident experts are in their R&D pipeline and their chances of approval.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NLSP-NLSP&v=1772545250654 "A chart showing the difference between the consensus forecast and the actual stock price. NLSP (NLSP)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
NLS Pharmaceutics is a Swiss biotech company developing drugs for the treatment of rare sleep disorders (narcolepsy) and ADHD. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in the treatment of these complex CNS disorders are possible.
Analysts' consensus forecast for the overall market share price
NLS Pharmaceutics (NLSP) is a Swiss biopharmaceutical company focused on sleep disorders. They are developing new drugs for the treatment of narcolepsy and ADHD. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D projects in one of the most complex and risky areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NLSP
NLS Pharmaceutics is a Swiss biotech focused on wakefulness. Their specialty is the R&D of drugs (Mazindol, Quilience) for the treatment of rare sleep disorders, primarily narcolepsy. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of approval.
AKIMA Market Segment Index - Pharma neurology
NLS Pharmaceutics (NLSP) is a Swiss biopharmaceutical company specializing in the central nervous system. They develop drugs for the treatment of sleep disorders (narcolepsy) and ADHD. This chart shows the average index for the segment. It helps investors assess how NLS's risks in this complex area of neuroscience compare to the sector average.
The AKIM Index for the overall market
NLS Pharmaceutics is a Swiss biopharmaceutical company developing treatments for central nervous system disorders (narcolepsy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how NLSP, the scientific story, compares to overall economic trends.
